Author response for "A greater proportion of participants with type 2 diabetes achieve treatment targets with IDegLira (insulin degludec/liraglutide) versus insulin glargine U100 at 26 weeks: DUAL VIII a randomized trial designed to resemble clinical practice"
Diabetes, Obesity and Metabolism（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要